The pressing need for effective cell therapy for the heart has led to the investigation of suitable cell sources for tissue replacement. In recent years, human pluripotent stem cell research expanded tremendously, in particular since the derivation of human-induced pluripotent stem cells. In parallel, bioengineering technologies have led to novel approaches for in vitro cell culture. The combination of these two fields holds potential for in vitro generation of high-fidelity heart tissue, both for basic research and for therapeutic applications. However, this new multidisciplinary science is still at an early stage. Many questions need to be answered and improvements need to be made before clinical applications become a reality. Here we discuss the current status of human stem cell differentiation into cardiomyocytes and the combined use of bioengineering approaches for cardiac tissue formation and maturation in developmental studies, disease modeling, drug testing, and regenerative medicine.
Introduction
Heart disease is a major life-threatening condition worldwide. A primary reason for the high incidence of cardiac disease is that the regenerative capacity of adult myocardium is very limited. Instead of regeneration, myocardial infarction is followed by the formation of fibrous scar tissue in the damaged area. 1, 2 The need for a therapy has triggered deep investigations to identify the proper cell source and strategy for functional regeneration of the heart. Cardiac stem cells, skeletal myoblasts, bone marrow derived cells, and peripheral mononuclear cells have been studied in animal models and in clinical trials, with limited tissue regeneration. 3, 4 Because of their unlimited capacity of self-renewal while virtually retaining differentiation potency, human pluripotent stem cells (hPSCs) may represent the most promising cell type for cardiac cell replacement therapy. Over the last decade, efforts have been made to develop methods for directed cardiac differentiation of hPSCs. Early studies 5 demonstrated feasibility of cardiomyocyte (CM) differentiation in vitro, while subsequent studies have led to the optimization of staged differentiation protocols. Although in vitro cardiac differentiation of PSCs has been improved in many respects, the strategies currently available still have limitations that need to be overcome before clinical trials. These limitations can be summarized as: (1) high variability of cardiac differentiation efficiency and reproducibility among different cell lines, (2) heterogeneity of the differentiated cardiac cell population, (3) difficulties in the scale-up to generate clinically relevant numbers of CMs, and (4) immaturity of the cells.
Recent advances in the development of engineered culture devices offer advantages over standard cell culture systems. 6 Combination of canonical stem cell biology with bioengineering tools might help overcome, or at least minimize, the aforementioned problems in cell derivation for potential clinical applicability. The current tissue engineering systems are based on biomaterial scaffolds, designed to serve as a cell culture niche, and bioreactors, designed to provide precise control of the cell culture environment, supply of nutrients and oxygen, and provision of physiologic regulatory factors. We discuss the impact of hPSC research on in vitro cardiac differentiation, and the use of new bioengineering approaches to improve cardiac cell culture and generate a faithful human heart tissue in a dish.
Cardiac development
Understanding heart development is fundamental for directing cardiac specification and differentiation starting from cells at a pluripotent state. Most of our knowledge of cardiomyogenesis comes from studies in the mouse model.
The developmental process of gastrulation first gives rise to the mesoderm. 7, 8 At embryonic day 5, mesoderm arises with NODAL signaling in the proximal epiblast, maintaining BMP4 (Bone Morphogenic Protein 4) expression in the extra-embryonic ectoderm. Other signaling, including Dkk1, Cer1, and Lefty1, is responsible for NODAL and WNT (homologue of Drosophila Wingless gene) signaling restriction to the posterior epiblast. Then, before the epithelial-mesenchymal transition of the anterior primitive ectoderm, WNT induces the expression of mesendodermal markers such as T (Brachyury), which together with Eomes is then involved in the expression of MESP1, 9, 10 described as the principal regulator of cardiac specification. 11 In the presence of DKK1, which inhibits the canonical WNT signaling, MESP can activate the differentiation of the cardiac progenitor cells. 11 Terminal CM differentiation is coordinated by complex interactions of transcription factors including Nkx2.5, Mef2C, Gata-4, and Tbx5. 12, 13 It has been shown that WNT canonical signaling maintains the cardiac progenitor cell pool while the NOTCH signaling controls their differentiation. 12, 13 The cardiac mesoderm progresses through major morphological changes forming the different heart compartments, 8 and further development toward the complete formation of the myocardium involves the BMP, WNT, and FGF (Fibroblast Growth Factor) pathways. 14 Interestingly, recent molecular analysis identified the BMP, FGF, activin/ NODAL, and WNTsignaling as the four key signaling mechanisms involved in the cardiac differentiation of induced pluripotent stem cells (iPSCs) and need to be regulated in a timely fashion, 15 indicating a meaningful biomolecular correlation between the natural heart development and the in vitro cardiac differentiation of hPSCs.
Deriving CMs from PSCs
Stem cell biology has had a great impact on envisioning new therapeutic modalities for the heart ever since the mouse ESCs were first derived 16 and even more after ESCs were also derived from humans. 17 The significance of these studies is in the isolation of a defined stem cell type that can indefinitely proliferate in vitro and at the same time is virtually able to give rise to any tissue, hence representing an ideal source for cell replacement therapy. Today, we are still facing two major obstacles to the use of hESCs for clinical therapy. First, human embryos are required for their derivation, raising ethical concerns. Because the clinical use of ESCs is only possible in heterologous fashion, lifelong immunosuppression of the patient would be necessary. Almost 10 years after the derivation of hESCs, these limitations have been largely overcome through another major advance in stem cell science-generation of the iPSCs that soon after being obtained from mouse 18 were also derived from human. 19, 20 The iPSC discovery has profoundly changed our understanding of cell plasticity, has resolved most issues associated with the use of hESCs, and opened the possibility for personalized regenerative medicine by autologous transplantation of patient-derived iPSCs.
CM differentiation of hPSCs can be achieved in different cell culture settings, by controlling key steps of the differentiation progression ( Figure 1 ). Many different methods Figure 1 Available cell culture systems and molecular components of the key steps in hPSC cardiomyocyte differentiation. One of the oldest systems used is the co-culture of the PSCs with the inducing endodermal cell line END-2. The EB format is based on a 3D aggregation system. The monolayer is widely used and many different protocols have been established with this format. The reagents here reported are used in different combination (see also for PSC differentiation into CMs have been investigated (see Table 1 for an overview of some of the relevant methods). The first protocols adopted were developed using hESCs and were based on the sole spontaneous differentiation. 5 Cells were induced to differentiate in three-dimensional (3D) structures-the embryoid bodies (EBs), or by using an inducing component-the END-2 endodermal cell line. 21, 22 In both cases, the processes were relying on poorly controllable paracrine effects, had relatively low differentiation efficiencies, and a well-defined molecular environment was lacking.
Recently established methods are based on the recapitulation of key mechanisms of the heart development in the embryo and involve temporal administration of specific molecules regulating specific signaling cascades. In this regard, the regulation of canonical WNT signaling is the most widely accepted approach to controlled differentiation into CMs. Following this concept, WNT3A, a WNT signaling activator, was applied during the first two days of differentiation of stem cells cultured in the EB format, 25 in order to mimic the early primitive streak/mesendoderm induction. The same pathway was then inhibited at a later stage with the small molecule IWR-1, 37 to achieve the cardiac mesoderm specification.
The laboratory of Dr Keller has developed a serum-free protocol for cardiac differentiation of EBs derived from hESCs and iPSCs at high efficiency and with deeper lineage characterization along the differentiation progression from the pluripotent state to beating differentiated cells. 26, 27 They described an early KDR positive cardiovascular progenitor cell population that can give rise to CMs as well as smooth muscle and endothelial cell both in vitro and in vivo after transplantation. 26 They also identified the fine regulation of the activin/NODAL and BMP signaling as crucial factors for optimal cardiac mesoderm specification and efficient CM differentiation. 27 The process of cardiac differentiation can be monitored by the flow cytometry analysis of a KDR/ PDGFRa positive population. The fine-tuning in downregulation of the aforementioned mechanisms at the cardiac mesoderm specification stage can be further improved with the employment of small molecules such as SB431542 and dorsomorphin (timing of administration between day 3 and 5). The concomitant use of the WNT inhibitor IWP-1 (between day 4 and 10) was also shown to improve the overall efficiency of differentiation. The efficiency of CM differentiation can be evaluated by the detection of the percentage of single cells positive for cardiac specific markers such as cardiac Troponin T (CTNT). The optimized protocol allowed achieving efficiency higher than 60% in CTNTþ cells.
Another system, based on forced cell aggregation in the EB format and the employment of bFGF and BMP4 without activin A, further improved the differentiation efficiency up to almost 90% of CMs. 30 Another group, again using the EB format with forced cell aggregation, proposed a protocol involving activin A, BMP4, and also WNT3a, KITLG, and VEGF in the first stage and resulting in similar efficiency. 38 Besides the END-2 co-culture protocol, which gives rise to CMs with a mostly ventricular phenotype, all hPSC-CM differentiation methods result in a mixed population of CM subtypes including atrial, ventricular, and nodal. Remarkably, a recent study proposing a new method for EB-derived hPSC-CM demonstrates how the use of the small molecule IWR-1, a canonical WNT signaling inhibitor, can result in fully ventricular-like CMs while the employment of DKK1 during the exact same temporal window results in almost 50% of ventricular-like, almost 50% of atrial-like, and a very small portion of nodal-like CMs. 38 Although the 3D EB format reproduces some aspects of the in vivo tissue architecture, it also poses several problems related to cell culture preparation such as the control of cell aggregation (both in terms of yield and size uniformity) and the maintenance of the suspension culture. The monolayer format is generally considered more reproducible and, in principle, a more suitable approach for the scale-up for clinical purposes. In addition, a 2D system guarantees a more homogeneous exposure of the cultured cells to the soluble environment and might thus contribute to reducing the differences in quality and quantity of CM differentiation between cell batches and between different cell lines.
In the last few years, many methods adopting the monolayer format have been developed. The first monolayer method proposed was based on high-density PSCs adherent on a Matrigel-coated surface in the Rosewell Park Memorial Institute (RPMI) 1640 medium. 33 The protocol included administration of a high dose of activin A, followed by BMP4 for four days. This protocol resulted in CM differentiation efficiencies of approximately 30%. Improvements were obtained with a Matrigel overlay (the so-called Matrigel sandwich) that facilitated epithelialmesenchymal transition before the addition of induction media, removal of insulin, addition of bFGF with activin A in the first stage, and addition of DKK1 in the second stage. 32 A similar approach was employed using a Matrigel overlay one day before the addition of differentiation medium and maintaining it also during induction with activin A, followed by a treatment with bFGF and BMP4. This method resulted in CM differentiation efficiencies of up to 98% of CTNT positive cells. 31 All cardiac differentiation methods, both in 3D and monolayer formats, are based on the use of cytokines for the activation or inhibition of the specific signaling pathways. The cytokines, beside their high cost that affects scaleup of cell differentiation protocols for clinical application, can also cause batch-to-batch variability in the quality of cell preparation. This in turn can hinder reproducibility of cell differentiation protocols even for the same cell line. An alternative approach, recently developed in the Palecek's laboratory, is based on a cytokine-free protocol, where the activation and downregulation of the WNT signaling are achieved by the sole use of small molecules. 34, 39 All protocols for cardiac differentiation of human stem cells in the monolayer format that have been developed thus far require supplementation of B27 to differentiation media, a compound originally designed for neuron cell cultures. 40 It is not fully understood to what extent this component is suitable for CM differentiation. Recent work in Wu's laboratory shows that removal of the B27 supplement and the use of only three basal components (l-ascorbic acid, rice-derived recombinant human albumin, and the classic RPMI 1640 medium) in combination with the small molecules result in CM differentiation efficiencies of over 85%. The cell preparation can be further enriched up to 95% of CMs by metabolic selection. 36 Moreover, this protocol was proven to be effective in 11 different iPSC lines, a remarkable number never reported before for any CM differentiation method. This work represents a major step toward eliminating line-to-line variability of cardiac differentiation in human stem cells.
CM maturation
To date, several research groups have established and validated reliable and efficient protocols for the differentiation of hPSC into CMs. However, the maturation of hPSC-CMs remains a major issue yet to be fully resolved. Postdifferentiation hPSC-CMs are inevitably immature, and the cell phenotype resembles that of a fetal rather than a postnatal cardiac cell. This becomes evident when multiple characteristic traits of the immature and mature CMs are compared. First, the morphological structure of in vitro hPSC-CMs is quite different from that of adult CMs. hPSC-CMs tend to have irregular shapes while the adult CMs maintain their cylindrical structure. 41 This difference is also reflected in the poor sarcomeric organization of hPSC-CMs when compared to that of adult hCMs. 42, 43 Another important indicator of CM maturation is the presence of T-tubules. Studies in rat CMs show that fetal cells lack T-tubule structures, which are present and fully developed in the postnatal cells. Different reports show that T-tubules are similarly rare or totally absent in hPSC-CMs, 43, 45 and that calcium transients are unsynchronized. 46 It has also been described how the metabolism of CMs goes through major changes during development. In the early phases, the metabolism of cardiac cells is mostly glycolytic, while during the later development and terminal differentiation, the mitochondrial oxidative capacity becomes higher and the metabolism relies mostly on fatty acid b-oxidation. 46 A recent paper demonstrated how hiPSC-CMs metabolic activity is mostly glycolytic, thus further proving the low level of maturity of the differentiated iPSC-CMs. 47 Another structural difference is in the localization of gap junction proteins. It is well known that in mature cells they accumulate at the intercalated disks, while in hPSC-CMs they tend to be evenly distributed at the circumference, thus again more closely resembling the structure of fetal cells. 48, 49 Finally, mature cells have higher expression levels of cardiac genes than hPSC-CMs. This is particularly evident for sarcomeric proteins, ion transport proteins, and calcium-related genes. 50, 51 The simplest, although not very practical, approach to CM maturation in vitro is the long-term culture of the differentiated cells. It has been observed that after 35 days in culture hPSC-CMs display ultrastructural maturation and exit the cell cycle. 43 After 90 days in culture CMs become more electrophysiologically mature in terms of action potential upstroke velocity, diastolic potential, and outward rectifier potassium current. 52 A recent study showed that after 120 days in culture CMs strongly increase their cell size, sarcomere length, percentage of multinucleated CMs, and anisotropy. 53 The simple prolongation of the time in culture can remarkably increase the maturation level of hPSC-CMs but has the undeniable downside of being time consuming and expensive.
Cardiac development is a complex process, evolving from an elaborated system of signaling molecules that have to be tightly coordinated in a spatial and temporal fashion (recently reviewed in the literature 15, 54 ). In addition, it must be considered that the heart is characterized by interactions of different cell types the function of which is orchestration by multiple signals such as molecular, electrical, and mechanical. 54 The design of an in vitro CM differentiation system for pharmacological studies and tissue replacement thus needs to take into account this complex landscape. The engineering approaches reviewed in the following section were designed to study the regulatory cascades and support the development of an effective system for generating hPSC-CMs.
Engineering PSC-derived CMs
Advanced engineering technologies can be exploited in order to increase the degree of control over the cell culture environment and thus obtain functionally mature CMs in an overall system that remains as faithful as possible to the natural heart physiology. [54] [55] [56] Several studies conducted in recent years (Figure 2 , Table 2 ) include: the use of biomaterials for proper seeding, 70 orientation and cell-cell and cellextracellular environment interaction, 57,71,72 bioreactors for constant molecular and fluidic control of the cell culture environment, 59, 73, 74 and the engineered platforms for providing combinations of mechanical and electrical stimuli. 72, [75] [76] [77] A simple example of the use of biomaterials for hPSC culture comes from the attempt to maintain pluripotency of hPSC and improve their growth in culture, while minimizing the amounts of culture media and the exposure to animal-derived components. Matrigel, a gelatinous protein mixture derived from a mouse cell line sarcoma, is the most commonly used substrate for cell adhesion and, in combination with the defined culture medium mTeSR, was identified as the most effective substrate. 60 Considerable efforts have been devoted to the development of hPSC culture systems free of animal-derived components, such as mouse embryonic fibroblasts, typically used as feeder cells, fetal bovine serum, and extracellular matrix proteins of animal source. 78 Alternative approaches use human cell feeder layers and medium supplemented with serum replacements. 79 Purified extracellular matrix molecules such as laminin, vitronectin, and collagen type I are also used as a structural substrate, as well as hyaluronic acid (HA) and calcium alginate hydrogels. Laminin and vitronectin supported the long-term expansion of hESCs in a defined culture medium both in the conventional monolayer culture and on 3D polystyrene microspheres. The expanded cells maintained high expression and karyotypic normality for over 20 passages. 80 A thorough study in which Matrigel was systematically replaced with defined medium supplements and ECM proteins showed that recombinant vitronectin was the optimal functional alternative for supporting sustained self-renewal and pluripotency of three different hESC lines. 81 hESCs were also successfully cultured on a type I collagen substrate without the need of feeders cells and in a defined serum-free medium. The same study also proved that hESCs could proliferate without bFGF supplements if heparin was added. 82 Vunjak-Novakovic's laboratory proposed the use of a completely synthetic hydrogel matrix, HA, to encapsulate and culture hESCs. 83 When encapsulated in 3D HA hydrogels cells preserved their normal karyotype and maintained their full differentiation capacity, which could be induced within the same hydrogel by simply altering soluble factors in culture environment. hESCs were also encapsulated in calcium alginate hydrogels and cultured for up to 260 days. 84 The authors proved the absence of unwanted cell differentiation along with the maintenance of cell pluripotency when exposed to a conditioned environment. ECM-derived hydrogels, a novel class of biomaterials, hold great promise for deriving hPSC-CM. Vunjak-Novakovic's laboratory, for example, used hydrogels composed of native heart ECM obtained from decellularized heart and blended with collagen without the addition of soluble cytokines. Such hydrogels were able to induce hESC differentiation into CMs. Higher contents of heart extracellular matrix resulted in further CM maturation as evidenced by the presence of striation, increased connexin 43 expression, and improved contractile properties. 62 This study brings us to the next key necessity for generating functional in vitro heart tissue: the achievement of a physiological 3D architecture of the aggregated cells. The most common approach is based on the suspension of cells in hydrogels in dedicated molds, favoring the spontaneous aggregation of cells in a 3D fashion, and the stabilization of the newly formed structure. 62 When adding two or more anchoring points to the molds, the forming tissue is poised to develop mechanical tension between them, to organize and align and thus push the maturation process further. Bursac's laboratory demonstrated that hESC-CMs seeded around elliptical posts in a 3D fibrin hydrogel system were aligned uniformly and highly organized. They also showed higher conduction velocity, sarcomere length, and contractile force, correlating with their increased expression of genes involved in cardiac contractile function and proving their advanced level of maturation. 63, 58 Recent work demonstrated the maturation of hESC-CMs encapsulated in resorbable gelatin hydrogels that were stimulated with cyclic uniaxial stretch. 67 When compared to unstretched controls, the stimulated constructs had an increased percentage of CTNT-positive cells, greater elongation, increased gap junction expression, better contractility, improved calcium handling, and higher expression level of relevant ion channel-associated genes. Furthermore, implantation of these constructs resulted in increased survival and engraftment of the transplanted cells in the stretched samples. 67 Similar to hESC-CM, iPSC-CMs also were successfully cultured in 3D hydrogel structures. 64 Cells were assembled in a 3D collagen hydrogel and exposed to uniaxial mechanical stimulation that markedly improved CM alignment, myofibrillogenesis, sarcomere formation, and cell hypertrophy. Interestingly, co-culture with endothelial cells resulted in increased CM proliferation, while the further addition of stromal cells favored the formation of vessel-like structures and simultaneously incremented active force upon increased resting length.
An interesting alternative to the scaffold-based aggregation for the construction of a 3D cardiac tissue is represented by the technology that uses temperatureresponsive polymer Poly N-isopropylacrylamide as substrate for cell culture. 85 With this technique, entire sheets of monolayered iPSC-CMs can be detached from the culture surface, fully preserving cell surface and extracellular components, and raising the possibility of fabricating cardiovascular tissues by overlaying multiple sheets. 69, 86 Another interesting approach was developed in Murry's laboratory 87 that involves spontaneous aggregation of hESC-CM during suspension culture on a rotating orbital shaker. Cells aggregated forming macroscopic disc-shaped patches of beating tissue with a 300-600 mm thickness. Prevascularization of cell sheets was achieved by co-culturing hESC-CM with human endothelial cells, vascular mural cells, and/or fibroblasts. 88, 89 In animal models, microvessels anastomosed with the host coronary circulation and delivered blood to the grafts. 89, 90 Cell sheet technology has been used to fabricate viable cardiac constructs from both hESCs and hiPSCs for drug testing 91 and implantation.
It has also been hypothesized that the stiffness of extracellular matrix is related to CM maturation. A major indicator of this concept is the progressive accumulation of collagenous extracellular matrix, and thus a proportionate increase in stiffness, by CMs from the embryonic to the postnatal stage. 46 In mouse studies, the elastic modulus, an indicator of the passive stiffness, has a threefold increase from embryo to the newborn animal. 92 Other studies with polyacrylamide gels with varying elastic moduli showed that hESC-CM morphology was affected in an analogous manner to that of neonatal rat CMs. 65 Following a similar approach, it was recently shown that both hESC-and iPSC-CMs generate more mechanical force when cultured on hydrogels with higher stiffness. 66 The laboratory of Levchenko 93 developed a nanofabricated PEG hydrogel substratum able to reproduce the nanostructure of the heart extracellular matrix with high fidelity and showed that rat CMs seeded in this substrate align and exhibit cell geometry, conduction velocity, and connexin 43 much more similar to those in the native heart when compared to the non-aligned CMs. It would be interesting to check if this result can be reproduced with iPSC-CMs.
Radisic's laboratory developed a novel engineering platform named Biowire, in which iPSC-CMs are placed in a polydimethylsiloxane channel surrounding a surgical suture in a collagen matrix. This resulted in cardiac cells aligned in 3D and were presenting well-developed striations. Electrical stimulation also improves cardiac tissue parameters, such as myofibril organization, conduction velocity, electrophysiological properties, and calcium handling. 68 Another important aspect of CM maturation is cellular cross-talk, a process in which non-myocyte cell types in the myocardium play a pivotal role. For example, it has been found that co-culture of non-CM cell populations is necessary during hPSC differentiation for the activation of important calcium handling proteins and ion channel proteins such as HCN4. 94 Interestingly, direct reprogramming of fibroblasts by genetic activation of three key transcription factors, Gata4, Mef2c, and Tbx5, although effective in achieving full differentiation, gives rise to immature hPSC-CMs. 95 The same reprogramming performed in vivo generates CMs with morphological and electrophysiological properties similar to those in mature adult cells. 96 This in turn indicates the great importance of establishing a native-like environment for cultured CMs and suggests that further in-depth studies of the key paracrine signals will be necessary to achieve complete in vitro maturation of hPSC-CMs.
Summary and future perspectives
Important advances have been made in both stem cell biology and cardiac tissue engineering over the last decade. However, despite the promising results and the great potential, many open questions remain. In terms of clinical application, the safety of hPSC needs to be addressed. Culture systems must ensure the complete removal of undifferentiated cells in the cell pool prepared for transplantation, in order to avoid potential tumorigenic effect. 97, 98 As discussed in this paper, another important issue is the presence of animal-derived components in the culture substrates and differentiation cocktails, which might carry undetected pathogens. Although some of the proposed alternatives to common cultures help approach the golden standard of animal-free conditions, they cannot be considered fully defined. An evident limitation would be the batch-to-batch variability of the components used. An ''ideal'' method would combine animal productfree culture, chemically defined matrix, and serum free medium. 78 The hiPSCs carry possible immune response potentials because of the genetic or epigenetic modifications required for their generation. The actual immunogenicity of iPSCs has not been fully defined even in the autologous settings. Syngeneic transplantation of undifferentiated iPSCs for teratoma formation resulted in T cell infiltration, even when the cells were generated with the episomal vector. 99 A different study showed no rejection after syngeneic transplantation of differentiated iPSCs and only minor immunogenic response after transplantation of undifferentiated cells. 100 Further studies will be necessary to make the future clinical application of iPSCs safe and effective.
Up until now, hESCs and hiPSCs were the only two hPSC types experimentally available. The laboratory of Mitalipov recently found that somatic cell nuclei can be reprogrammed by nuclear transfer into oocytes in humans, thus generating the so-called nuclear transfer pluripotent stem cells (NT-PSCs). 101 This finding was then confirmed by Egli's laboratory that reprogrammed nuclei of cells from type 1-diabetes patients using the same strategy. 102 NT-PSCs will probably be soon commonly used in research laboratories and in the near future might represent an alternate powerful tool for cell therapy of many tissues, including heart.
Many protocols showed that high efficiency of CM derivation from hPSCs is now possible. Although several published methods claim the reduction or elimination of inter-line variability, high reproducibility and standardization of efficient CM differentiation from different cell lines is still a challenge. It is undeniable that even the most established protocols can lose their effectiveness when adopted by other research laboratories and applied to different lines or the same lines at different passage numbers. Moreover, the scaling up of CM production to billions of cells, as required for cell replacement therapies, together with their integration with the most suitable bioengineering platforms, will need to be achieved. Some efforts have been already made in the CM differentiation approaches 103 and, more in general, the removal of expensive reagents and progressive minimization of the size of culture systems are contributing to lowering the costs and therefore increasing the feasibility of the clinical therapy.
In the last year, a remarkable preclinical study showed that hESC-CMs can extensively remuscularize infracted heart in monkey 104 and electromechanically couple with the host tissue. In addition, the study shows that there was neither tumor formation nor fatal ventricular arrhythmias and that clinical scale production of hPSC-CM is possible, 104 making a major advance toward their applicability in patients. However, the low replica number used due to the high cost of this animal model makes it difficult to achieve statistical significance. 104 Moreover, the size of the injury in this model of ischemia was smaller than the infarcts of patients that would benefit from this type of therapy and that therefore might possibly suffer more severe arrhythmias. 104 Larger studies will be necessary to assess the actual efficacy and safety of this promising therapeutic system.
Approaches at multiple levels are still needed to ensure control of different synergic cues for an efficient reproduction of the natural developmental maturation to achieve full functionality of the cardiac tissue for basic and applicative research purposes. Further interdisciplinary efforts of cell biologists and bioengineers are critically important for further improvements that will make clinical trials of stem cellbased heart regeneration a realistic possibility.
Authors' contribution: DS, EC, and GV-N have jointly planned and written the manuscript. GV-N approved the final version of the manuscript.
